Breast scintigraphy with 99mTc-pertechnetate and 67Ga-citrate.
Radionuclide breast scintigraphy was evaluated as a noninvasive tumor-localizing modality. Technetium-99m-pertechnetate (99mTcO4) demonstrated good correlation between malignancy and postive scintigraphy (88% accuracy in 16 cases of breast carcinoma). The high false-positive rate (29% of proven benign breast disease) limits the use of 99mTcO4 as an aid to differential diagnosis. Gallium-67-citrate (67Ga) is limited as a diagnostic adjunct (localizing in only five of ten breast malignancies). Refined techniques of positioning, shielding, gamma camera imaging, and computer assistance have helped in visualizing abnormal radionuclide accumulation.
D000328:Adult; D001941:Breast Diseases / Q000175:diagnosis / Q000000981:diagnostic imaging; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging; D003560:Cysts / Q000175:diagnosis / Q000000981:diagnostic imaging; D005189:False Positive Reactions; D005260:Female; D005708:Gallium; D006801:Humans; D008327:Mammography; D008875:Middle Aged; D011868:Radioisotopes; D011877:Radionuclide Imaging; D013667:Technetium; D014986:Xeroradiography
D011868:Radioisotopes; D013667:Technetium; D005708:Gallium